Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Product Revenues – net of Discounts and Rebates		$ 100,932	$ 124,972	$ 264,484	$ 230,646
Cost of Revenues		50,051	89,564	123,323	155,001
Gross Profit		50,881	35,408	141,161	75,645
Research Revenues		206,939	728	299,670	30,359
Net Revenue		257,820	36,136	440,831	106,004
Operating Expenses:
Research and Development		249,884	3,095,326	657,506	3,432,508
General and Administrative Expenses		1,612,764	1,129,560	3,299,028	2,204,694
Total Operating Expenses		1,862,648	4,224,886	3,956,534	5,637,202
Loss from Operations		(1,604,828)	(4,188,750)	(3,515,703)	(5,531,198)
Interest Expense		(1,221)	(3,621)	(3,011)	(5,023)
Change in Fair Value of Derivative Liabilities		(140,447)	(1,101)	(135,342)	1,739,746
Other Income, net		13,066	19,684	43,388	50,735
Total Interest and Other (Expense) Income, net		(128,602)	14,962	(94,965)	1,785,458
Loss from Operations before Provision for Income Taxes		(1,733,430)	(4,173,788)	(3,610,668)	(3,745,740)
Provision for Income Taxes (Note 9)		1,500	438	1,563	501
Net Loss including Noncontrolling Interest		(1,734,930)	(4,174,226)	(3,612,231)	(3,746,241)
Net Loss – Noncontrolling Interest		(1,204)	(1,471)	(1,956)	(3,956)
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(1,733,726)	(4,172,755)	(3,610,275)	(3,742,285)
Comprehensive Loss:
Net Loss		(1,734,930)	(4,174,226)	(3,612,231)	(3,746,241)
Unrealized Foreign Currency Translation Gain (Loss)		17,242	3,137	7,338	(757)
Total Comprehensive Loss		(1,717,688)	(4,171,089)	(3,604,893)	(3,746,998)
Net Loss – Noncontrolling Interest		(1,204)	(1,471)	(1,956)	(3,956)
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(1,716,484)	(4,169,618)	(3,602,937)	(3,743,042)
Cumulative Dividends on Series A Preferred Stock		(126,705)	(117,881)	(244,863)	(235,762)
Net Loss - attributed to common stockholders		$ (1,843,189)	$ (4,287,499)	$ (3,847,800)	$ (3,978,804)
Net Loss per Common Share:
Basic (in Dollars per share)		$ (1.25)	$ (21.12)	$ (2.79)	$ (21.41)
Diluted (in Dollars per share)		$ (1.25)	$ (21.12)	$ (2.79)	$ (21.41)
Weighted Average Number of Common Shares Outstanding(1)
Basic (in Shares)	[1]	1,472,891	202,967	1,378,700	185,861
Diluted (in Shares)	[1]	1,472,891	202,967	1,378,700	185,861

[1] Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.